Management of Medication Regimens in Post-Bypass Patients with Chronic Kidney Disease on Hemodialysis

Introduction to Medication Management

The European Society of Cardiology recommends clopidogrel 75 mg maintenance dose for post-PCI/CABG patients, with a duration of at least 6-12 months depending on the type of stent and bleeding risk, according to the ESC/EACTS 2018 guidelines 1, 2, 3
The American College of Cardiology/American Heart Association recommends beta-blockers for all post-MI and heart failure patients with EF ≤40%, with a target dose of bisoprolol 10 mg once daily (or the maximum tolerated dose) for EF 39% 4
The American College of Cardiology/American Heart Association recommends ACE inhibitors for all patients with LVEF ≤40%, hypertension, diabetes, or chronic kidney disease, with ARBs as an alternative for those intolerant to ACE inhibitors 8, 7

The European Society of Cardiology recommends statin high-dose therapy for all post-revascularization patients, with atorvastatin 80 mg as the recommended dose for secondary prevention of cardiovascular disease 1, 2, 4
Prasugrel or ticagrelor are more potent and recommended as the first choice for acute coronary syndrome, although data on end-stage kidney disease is limited 1, 2

The American College of Cardiology/American Heart Association recommends spironolactone or eplerenone for post-MI patients with EF ≤40% and diabetes or heart failure, with careful monitoring of potassium levels, especially in hemodialysis patients 8, 7
The American College of Cardiology/American Heart Association recommends careful monitoring of potassium levels and blood pressure in hemodialysis patients, especially when adding RAAS inhibitors or aldosterone antagonists 5, 6, 9

Regular monitoring of serum potassium, blood pressure, and cardiac function is necessary for hemodialysis patients on these medication regimens, with target blood pressure <140/90 mmHg and potassium levels 4.0-5.0 mEq/L 5, 6, 9
Echocardiography should be repeated within 3-6 months to evaluate the response to therapy, and hemoglobin and bleeding risk should be monitored, especially with antiplatelet therapy 4, 6